Hearts & Minds Blog

Reflecting on a Focused 2017 and Looking Ahead to a Transformational 2018

Tim Mayleben

President and Chief Executive Officer

The past year was marked by tremendous progress for our bempedoic acid-based franchise – perhaps most importantly the achievement of… more

Important Bempedoic Acid-Based Franchise Progress Updates

Tim Mayleben

President and Chief Executive Officer

Last week was exciting for us at Esperion as we reported on tremendous progress achieved in enrolling patients for our… more

The Bempedoic Acid / Ezetimibe Combo Pill: Our Leading Complementary, Non-statin, Oral Therapy

Marianne Andreach

Senior Vice President, Strategic Marketing and Product Planning

This week we announced a major milestone: the U.S. Food and Drug Administration (FDA) confirmed the regulatory pathway to approval… more

Setting the Record Straight: The Facts About Bempedoic Acid

Tim Mayleben

President and Chief Executive Officer

We recently became aware of comments published containing misinterpretations or intentionally inaccurate statements regarding Esperion and bempedoic acid.  As the… more

ACC Scientific Session Reflections: A Conversation Among Members of The Lipid Management Team

Tim Mayleben

President and Chief Executive Officer

Mary McGowan

Chief Medical Officer

Marianne Andreach

Senior Vice President, Strategic Marketing and Product Planning

Last week The Lipid Management team attended the American College of Cardiology (ACC) 66th Annual Scientific Session in Washington D.C…. more